SARS-CoV-2 S protein (RBD, 319-541 aa) Monoklonaler Antikörper
SARS-CoV-2 S protein (RBD, 319-541 aa) Monoklonal Antikörper für Neutralization, WB, ELISA
Wirt / Isotyp
Maus / IgG1
Getestete Reaktivität
Virus und mehr (2)
Anwendung
WB, Neutralization, ELISA
Konjugation
Unkonjugiert
CloneNo.
1H3E9
Kat-Nr. : 67758-1-Ig
Synonyme
Galerie der Validierungsdaten
Geprüfte Anwendungen
Erfolgreiche Detektion in WB | Ag30688 |
Erfolgreiche Neutralization | Recombinant protein |
Empfohlene Verdünnung
Anwendung | Verdünnung |
---|---|
Western Blot (WB) | WB : 1:5000-1:50000 |
NEUTRALIZATION | NEUTRALIZATION : 1:10-1:100 |
It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
Sample-dependent, check data in validation data gallery |
Veröffentlichte Anwendungen
WB | See 6 publications below |
Produktinformation
67758-1-Ig bindet in WB, Neutralization, ELISA SARS-CoV-2 S protein (RBD, 319-541 aa) und zeigt Reaktivität mit Virus
Getestete Reaktivität | Virus |
In Publikationen genannte Reaktivität | human, Maus |
Wirt / Isotyp | Maus / IgG1 |
Klonalität | Monoklonal |
Typ | Antikörper |
Immunogen | SARS-CoV-2 S protein (RBD, 319-541 aa) fusion protein Ag30688 |
Vollständiger Name | SARS-CoV-2 Spike Protein |
Berechnetes Molekulargewicht | 141 kDa |
GenBank-Zugangsnummer | NC_045512 |
Gene symbol | COVID-19 S Protein |
Gene ID (NCBI) | 43740568 |
Konjugation | Unkonjugiert |
Form | Liquid |
Reinigungsmethode | Protein-A-Reinigung |
Lagerungspuffer | PBS mit 0.02% Natriumazid und 50% Glycerin pH 7.3. |
Lagerungsbedingungen | Bei -20°C lagern. Nach dem Versand ein Jahr lang stabil Aliquotieren ist bei -20oC Lagerung nicht notwendig. 20ul Größen enthalten 0,1% BSA. |
Hintergrundinformationen
Coronaviruses (CoVs) infect human and animals and cause varieties of diseases, including respiratory, enteric, renal, and neurological diseases. CoV uses its spike protein to recognize ACE2 as its receptors and mediate membrane fusion and virus entry into host cells(PMID: 32221306). Each monomer of trimeric S protein is about 180 kDa, and contains two subunits, S1 and S2,S1 recognizes and binds to host receptors, and subsequent conformational changes in S2 facilitate fusion between the viral envelope and the host cell membrane(PMID: 19198616). Although the amino acid sequences of the S-glycoprotein were found to be different between the various HCoV, the structures showed high similarity, but the best 3D structural overlap shared by SARS-CoV and SARS-CoV-2, consistent with the shared ACE2 predicted receptor (PMID: 32522207). The spike protein of CoVs can be a target for vaccine and therapeutic development (PMID: 19198616).
Lyophilized format of this product is available.
Protokolle
Produktspezifische Protokolle | |
---|---|
WB protocol for SARS-CoV-2 S protein (RBD, 319-541 aa) antibody 67758-1-Ig | Protokoll herunterladen |
Standard-Protokolle | |
---|---|
Klicken Sie hier, um unsere Standardprotokolle anzuzeigen |
Publikationen
Species | Application | Title |
---|---|---|
Acta Pharm Sin B A novel heterologous receptor-binding domain dodecamer universal mRNA vaccine against SARS-CoV-2 variants | ||
J Med Virol A novel three-plasmid packaging system for chimeric SFV/SIN VRPs derived from Semliki Forest virus and Sindbis virus as a candidate gene delivery vector | ||
Mol Genet Genomics Optimization of mammalian expression vector by cis-regulatory element combinations | ||
Adv Healthc Mater Black Phosphorus Nanosheets Assist Nanoerythrosomes for Efficient Mrna Vaccine Delivery and Immune Activation | ||
Microbiol Spectr Cytomegalovirus-vectored COVID-19 vaccines elicit neutralizing antibodies against the SARS-CoV-2 Omicron variant (BA.2) in mice |